
Opinion|Videos|April 25, 2025
Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice
Author(s)Alexandra K. Golant, MD
Alexandra Golant, MD discusses how cost considerations, insurance barriers, formulary restrictions, and effective caregiver education about proper application will significantly impact the widespread adoption of ruxolitinib cream in pediatric dermatology practice.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- Beyond efficacy and safety, what other factors—such as cost, insurance coverage, or caregiver education—will determine how widely ruxolitinib cream is adopted in pediatric dermatology, specifically in younger children?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
























